Targeting the CHK2-YBX1&YBX3 hub enhances immune checkpoint blockade response in gliomas, improving survival (ref: Ali doi.org/10.1093/neuonc/)
SPP1+ macrophages play a critical role in hypoxic adaptive tumor growth and response to anti-PD-1 therapy (ref: Zhang doi.org/10.1093/neuonc/)
Spatial transcriptomics reveals lack of response to PD-1 blockade in recurrent glioblastoma, indicating challenges in immunotherapy (ref: Artzi doi.org/10.1007/s00401-025-02937-9/)
Multi-omics approaches identify metabolic and immune subtypes in gliomas, enhancing classification and prognostic assessment (ref: Li doi.org/10.1200/PO-24-00928/)
Intratumoral heterogeneity in glioblastoma complicates treatment, with NUCB2 identified as a key factor in tumor aggression (ref: Huang doi.org/10.1111/jcmm.70814/)
Innovative glioma-on-chip models recapitulate the tumor microenvironment, improving evaluation of therapeutic responses (ref: Terrassoux doi.org/10.1002/smll.202505343/)
An optimized tissue sampling scheme guided by MRI features reveals significant intratumoral heterogeneity in glioblastoma (ref: Wang doi.org/10.1038/s41598-025-17539-4/)
Protein-based classification reveals an immune-hot subtype in IDH mutant astrocytoma associated with worse prognosis (ref: Tang doi.org/10.1016/j.ccell.2025.08.006/)